KALA BIO (KALA) 2025 Conference June 05, 2025 01:25 PM ET Speaker0 Go ahead and start. Welcome, everyone. First of all, I wanted to thank the Jefferies team for inviting us to provide an ups oh, I need to find the way. An update on Kala and remind everyone there will be likely some forward looking statements. So, Kala is a leader, in the emerging field of mesenchymal stem cell secretomes, and our focus is on rare ophthalmic diseases. We have an ongoing pivotal trial with our lead product, KPI o one two, for ...

Ms. Kline to lead Palvella’s commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline’s leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability ...